EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743

Arnaud Scherpereel iD, Paul Baas iD, Anna K Nowak iD, Anne S Tsao iD, Nobukazu Fujimoto, Solange Peters iD, Aaron S Mansfield iD, Sanjay Popat iD, Yolanda Bautista Aragon, Toby Talbot, Francesco Grossi iD, Dariusz Kowalski iD und 8 weitere

Journal of Clinical Oncology · 20.03.2026 · 44 (9) · 742-749

DOI: 10.1200/jco-25-01328 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.03.2026. Verfasst von Arnaud Scherpereel und 19 weiteren Autor:innen. Beteiligte Einrichtung: University of Lille, CHU Lille, INSERM U1189 OncoThAI, ONCOLille, Lille, France. Hauptthemen laut MEDLINE: Ipilimumab, Antineoplastic Combined Chemotherapy Protocols, Nivolumab, Pleural Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this 5-year follow-up from the CheckMate 743 study in patients with unresectable pleural mesothelioma (PM), we evaluated updated efficacy and safety outcomes and biomarkers and performed treatment-switching analyses with first-line nivolumab plus ipilimumab versus chemotherapy. With a median follow-up of 66.8 months, nivolumab plus ipilimumab demonstrated continued overall survival (OS) benefit versus chemotherapy in all randomly assigned patients (5-year OS rates, 14% v 6%; hazard ratio [HR], 0.74 [95% CI, 0.62 to 0.88]); similar benefit was observed regardless of tumor histology. Of biomarker-evaluable patients treated with nivolumab plus ipilimumab (n = 242), high baseline monocytic myeloid-derived suppressor cell (M-MDSC) levels correlated with worse OS versus low M-MDSC levels (HR, 1.25 [95% CI, 1.09 to 1.43]). After adjusting for 24% of patients in the chemotherapy arm who received subsequent immunotherapy, nivolumab plus ipilimumab demonstrated continued OS benefit versus chemotherapy (HR, 0.64 [95% CI, 0.53 to 0.78]). No new safety signals were observed. These results demonstrate long-term, durable clinical benefit with nivolumab plus ipilimumab versus chemotherapy, which continued to be preserved even after treatment-switching adjustment in the chemotherapy arm. Exploratory analyses suggested greater benefit with nivolumab plus ipilimumab in the low M-MDSC subgroup. These results further support first-line nivolumab plus ipilimumab as standard of care for unresectable PM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IpilimumabAntineoplastic Combined Chemotherapy ProtocolsNivolumabPleural NeoplasmsMesotheliomaHumansFemaleMaleAgedMesothelioma, MalignantMiddle AgedTreatment Outcome

Substanzen

IpilimumabNivolumab

Autor:innen und Institutionen

  • University of Lille, CHU Lille, INSERM U1189 OncoThAI, ONCOLille, Lille, France.
  • The Netherlands Cancer Institute and Leiden University Medical Center, Amsterdam, the Netherlands.
  • University of Western Australia, Perth, WA, Australia.
  • University of Texas MD Anderson Cancer Center, Houston, TX.
  • Okayama Rosai Hospital, Okayama, Japan.
  • Lausanne University Hospital, Lausanne, Switzerland.

ORCID-Profile: Arnaud Scherpereel, Paul Baas, Anna K Nowak, Anne S Tsao, Solange Peters, Aaron S Mansfield, Sanjay Popat, Francesco Grossi, Dariusz Kowalski, Andrés Felipe Cardona, Adam Lee, Yu-Han Hung, Gérard Zalcman

Zitieren

APA

Scherpereel, A., Baas, P., Nowak, A. K., Tsao, A. S., Fujimoto, N., Peters, S., Mansfield, A. S., Popat, S., Bautista Aragon, Y., Talbot, T., Grossi, F., Kowalski, D., Kaplan, M. A., Cardona, A. F., Soomro, R., Hu, N., Lee, A., Ip, V., Hung, Y. H., & Zalcman, G. (2026). Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743. Journal of Clinical Oncology, 44(9), 742-749. https://doi.org/10.1200/jco-25-01328

Vancouver

Scherpereel A, Baas P, Nowak AK, Tsao AS, Fujimoto N, Peters S, et al. Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743. Journal of Clinical Oncology. 2026;44(9):742-749. doi:10.1200/jco-25-01328

BibTeX
@article{Scherpereel2026,
  author = {Scherpereel, Arnaud and Baas, Paul and Nowak, Anna K and Tsao, Anne S and Fujimoto, Nobukazu and Peters, Solange and Mansfield, Aaron S and Popat, Sanjay and Bautista Aragon, Yolanda and Talbot, Toby and Grossi, Francesco and Kowalski, Dariusz and Kaplan, Muhammet A and Cardona, Andrés Felipe and Soomro, Raheela and Hu, Nan and Lee, Adam and Ip, Virginia and Hung, Yu-Han and Zalcman, Gérard},
  title = {Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {9},
  pages = {742--749},
  doi = {10.1200/jco-25-01328}
}
Kostenlos starten →